Schayowitz Adam 4

What Happened
Adam Schayowitz, EVP and Head of Research & Development at Zymeworks (ZYME), received three equity awards on April 9, 2026: 70,000 stock options, 47,000 restricted stock units (RSUs), and 76,000 performance restricted stock units (PSUs). Each award was reported at $0.00 per share (award/grant), so there was no immediate cash paid or proceeds. The 76,000 PSUs represent the maximum possible payout (200% of a 38,000 target) contingent on meeting specified total shareholder return (TSR) goals.

Key Details

• Transaction date: April 9, 2026 (filed Apr 10, 2026) — filing appears timely.
• Awards and reported amounts: 70,000 (stock options), 47,000 (RSUs), 76,000 (PSUs — maximum potential). All reported at $0.00 (awarded).
• Vesting / payout mechanics:
  • Stock options: 25% vest on first anniversary, then remaining shares vest in 36 equal monthly installments (see F1).
  • RSUs: vest in four equal annual installments beginning on the first anniversary (see F2, F3).
  • PSUs: payout is performance-based over a three-year TSR performance period ending Jan 12, 2029; payout ranges from 50% to 200% of the 38,000 target (76,000 max). PSUs generally vest only at the end of the performance period and subject to continued service, with limited exceptions (see F4, F5).
• Shares owned after transaction: not specified in the provided excerpt.
• Transaction code: A = award/grant (derivative awards), not a market buy or sale.

Context
These were grants of derivative awards, not open-market purchases or sales. Stock options give the right to buy shares subject to vesting; RSUs convert to shares as they vest; PSUs pay out only if performance targets are met over the performance period. There was no immediate cash outflow or inflow for the insider. Awards like these are common compensation tools and do not by themselves indicate the insider’s view of near-term stock performance.